Lifeline Biotechnologies Updates Company’s Website, FDA Consultant’s Report and Leeb Brokerage Services
May 12 2010 - 12:41PM
Business Wire
Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO) today
announced the completion of the updating and launch of its website,
www.lbti.com.
Jim Holmes, Lifeline's CEO, said, “The website has been
comprehensively updated providing extensive information on the
company, its history and current affairs. The site includes:
Company Information, Products & IP, Investor Relations,
Publications and Whitepapers as well as Contact Forms. The updated
information addresses many of the questions recently posed by the
Company’s shareholders and interested parties. We believe you will
find the new information about the Company and its First Warning
System™ to be informative regarding important aspects of the
Company and our business.
“Many of our shareholders are eager and looking forward to the
pending FDA Consulting Firm’s report. We have been assured the
report is nearing completion. We expect the report to guide us in
the preparation and submission of our 510(k) application to the
FDA. Clearance of the 510(k) will further our commercialization
efforts to bring the First Warning System™ to market.
“Concerning the recent SEC action against Leeb Brokerage
Services and several of its associates, we again confirm that the
Company has no knowledge of or association with Leeb and its
alleged illegal activities. The SEC action against Leeb has
resulted in DTC suspending their services of Lifeline. We have been
in communication with DTC and are in the process of providing them
information that is expected to confirm that all trading shares
issued by Lifeline are in accordance with regulatory requirements.
If DTC agrees, then DTC services are expected to be reestablished
for Lifeline.”
Safe Harbor: This release includes forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 27E of the Securities Act of 1934. Statements contained in
this release that are not historical facts may be deemed to be
forward-looking statements. Investors are cautioned that
forward-looking statements are inherently uncertain. Actual
performance and results may differ materially from that projected
or suggested herein due to certain risks and uncertainties
including, without limitation, the ability to obtain financing,
successful development of the Company's product or market
acceptance of the product and regulatory and shareholder approval
for anticipated actions.
Lifeline Biotech (CE) (USOTC:LLBO)
Historical Stock Chart
From Nov 2024 to Dec 2024
Lifeline Biotech (CE) (USOTC:LLBO)
Historical Stock Chart
From Dec 2023 to Dec 2024
